Ligand Pharma (LGND) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq eyes lower open after midterms-fueled surge as chip, data center stocks fall
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Apple seeks to raise up to $7 billion in seven-tranche bond offering
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $314.85 -0.4%
Financial Fact:
General and administrative: 6.31M
Today's EPS Names:
KELYA, ROX, KEEL, More
Financial Fact:
General and administrative: 6.31M
Today's EPS Names:
KELYA, ROX, KEEL, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q3 EPS of $0.62, $0.03 better than the analyst estimate of $0.59. Revenue for the quarter came in at $21.6 million versus the consensus estimate of $23.13 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Becton Dickinson (BDX) Tops Q4 EPS by 8c; Offers Guidance
- Wendy's (WEN) Tops Q3 EPS by 3c
- Vericel (VCEL) Tops Q3 EPS by 21c; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
